Dr. Srijan Acharya | Molecular Pharmacology | Excellence in Research

Dr at St. Jude Children’s Research Hospital, United States

Srijan Acharya is a dedicated scientist with expertise in molecular pharmacology and cancer genomics. He is currently a Post-Doctoral Research Fellow at St. Jude Children’s Research Hospital, focusing on childhood cancer research. With 32 published scientific articles and a total citation count of over 385, his work has contributed significantly to biomarker discovery, receptor pharmacology, and immuno-oncology. His research aims to address therapeutic resistance in pediatric malignancies through small molecule screening. Srijan is fluent in English, Bangla, and Hindi, with basic knowledge of Korean.

Profile

🎓 Education

PhD in Molecular Pharmacology from Chonnam National University, South Korea (2020). M.Sc. in Biotechnology from North South University, Bangladesh (2015). BPHRM in Pharmacy from East West University, Bangladesh (2012). His academic journey has provided a strong foundation in receptor pharmacology and molecular biology, guiding his transition into cancer research.

💼 Experience

Post-Doctoral Research Fellow, Pharmacy Department, St. Jude Children’s Research Hospital, USA (2023-Present). Post-Doctoral Research Fellow, Pathology Department, Mitchell Cancer Institute, USA (2020-2023). Executive Officer, Research and Development, Square Pharmaceutical PLC, Bangladesh (2012-2013). His experience spans academia and industry, with a focus on cancer research, receptor signaling, and small molecule screening.

🏆 Awards and Honors

Inducted into Sigma Xi, The Scientific Research Honor Society (2023). Recognized in Who’s Who in America by Marquis (2023). Young Investigator Award at AACR conference by AAISCR (2022). Best Presenter Award from China Pharmaceutical University (2021). Global Scholarship from Chonnam National University, Korea (2015). These accolades reflect his significant contributions to molecular pharmacology and cancer research.

🔬 Research Focus

Srijan’s research primarily investigates the role of molecular signaling in cancer, focusing on the interaction of nicotine receptors with GPCRs and their impact on cancer progression. At St. Jude, his work focuses on childhood cancers, particularly Ewing sarcoma and rhabdomyosarcoma. He uses small molecule screening to discover potential therapeutic agents and aims to overcome therapeutic resistance in pediatric cancers.

Conclusion

Srijan Acharya is a highly accomplished and promising researcher whose contributions to cancer pharmacology and molecular biology are noteworthy. His interdisciplinary research approach, combined with his dedication to advancing pediatric oncology, positions him as a leader in the field. With continued mentorship and broader collaborative efforts, Acharya is well poised for even greater achievements, further solidifying his place as an influential scientist in the biomedical community.

📚Publications

Title: Unveiling the intracellular dynamics of α4β2 nAChR-mediated ERK activation through the interplay of arrestin, Gβγ, and PKCβII
Year: 2024
Authors: Dooti K, Acharya S, Wang S, Kim K.M.

Title: Biphasic transcriptional and posttranscriptional regulation of MYB by androgen signaling mediates its growth control in prostate cancer
Year: 2023
Authors: Acharya S, Anand S, Khan MA, Zubair H, Srivastava SK, Singh S, Singh AP

Title: MYB exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostate cancer
Year: 2023
Authors: Md Khan, S Acharya, S Anand, F Sameeta, P Pramanik, C Keel, S Singh, James E Carter, S Dasgupta, A Singh

Title: Comparative study of the molecular mechanisms underlying the G protein and β-arrestin-dependent pathways that lead to ERKs activation upon stimulation by dopamine D2 receptor
Year: 2023
Authors: Liu H, Acharya S, Sudan SK, Hu L, Wu C, Cao Y, Li H, Zhang X

Title: Frequent loss of cacna1c, a calcium voltage-gated channel subunit is associated with lung adenocarcinoma progression and poor prognosis
Year: 2023
Authors: Dasgupta, S., Acharya, S., Khan, M. A., Pramanik, P., Marbut, S. M., Yunus, F., Galeas, J. N., Singh, S., Singh, A. P., and Dasgupta, S.

Title: Nicotine causes alternative polarization of macrophages via Src-mediated STAT3 activation: Potential pathobiological implications
Year: 2022
Authors: Acharya S, Saranyutanon S, Deshmukh SK, Khan MA, Singh S, Singh AP

Title: β-Arrestin1 and GRK2 play permissive roles in Src-mediated endocytosis of α4β2 nicotinic acetylcholine receptor
Year: 2021
Authors: Acharya S, Kundu D, Kim KM

Title: Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease
Year: 2021
Authors: Acharya S, Kim KM

Title: Clinicopathologic significance and race-specific prognostic association of MYB overexpression in ovarian cancer
Year: 2021
Authors: Miree, O., Srivastava, …Acharya S.et al.

Title: Metabotropic signaling cascade involved in α4β2 nicotinic acetylcholine receptor-mediated PKCβII activation
Year: 2020
Authors: Acharya S, D. Kundu, H.J. Choi, and K.M. Kim

Title: Catalpol and Mannitol, Two Components of Rehmannia glutinosa, Exhibit Anticonvulsant Effects Probably via GABAA Receptor Regulation
Year: 2019
Authors: Acharya S, Kim M., Botanas C. J., Custodio R. J., Lee H. J., Sayson L. V., Kim H. J.

Title: Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors
Year: 2017
Authors: Paudel S, Acharya S, Yoon G, Kim K.M., & Cheon S.H.

Dr. Dana Laor | Molecular Biology| Best Researcher Award

Profile Summary

Dr. Dana Laor Bar-Yosef is a distinguished molecular biologist renowned for her groundbreaking research in metabolic disorders. She completed her undergraduate studies in biology at the Hebrew University of Jerusalem, followed by M.Sc. and Ph.D. training at Tel Aviv University under Prof. Martin Kupiec. Her Ph.D. research elucidated the roles of TOR protein kinase in cell signaling and amino acid homeostasis using yeast models. Joining Prof. Ehud Gazit’s lab in 2015, she established innovative in vivo models for studying inborn errors of metabolism (IEMs), leading to significant insights and potential therapeutics. Dr. Laor Bar-Yosef’s expertise spans over 15 years, guiding her leadership of the metabolic research group and pioneering the concept of “Metabolostasis.” Her contributions have been recognized with prestigious awards, including the 2020 Ziegler Award, affirming her exceptional impact on medical research in metabolic disorders.

Professional Profiles

Scholar Profile

Education🎓

Postdoctoral Researcher in Molecular Biology and Nanotechnology Tel Aviv University, Tel Aviv 2015-2018, Ph.D. in Molecular Biology
Tel Aviv University, Tel Aviv 2009-2014 Thesis title: “The role of TOR in rapamycin response in the fission yeast” Advisors: Prof. Martin Kupiec and Prof. Ronit Weisman. M.Sc. in Genetics Tel Aviv University, Tel Aviv 2007-2009 Thesis title: “The TOR pathway regulates cellular growth, gene silencing and telomere length maintenance in the fission yeast” Advisors: Prof. Martin Kupiec and Prof. Ronit Weisman. B.Sc. in Biology
The Hebrew University, Jerusalem 2003-2006

🔬 Researcher Experience

Head of the Metabolic Research Group Shmunis School of Biomedicine and Cancer Research, Tel Aviv University 2018-Present, Postdoctoral Research School of Molecular Cell Biology and Biotechnology, Tel Aviv University 2015-2018, Graduate Research Department of Microbiology and Biotechnology, Tel Aviv University 2007-2014

Professional Development 📈

Women Executive Launchpad in HealthTech 8400 Health Network 2022-2023, Health Care Technological Innovation – From Idea to Commercialization Coller School of Management at Tel-Aviv University and Lahav Executive Education 2022

Teaching Experience📚

Instructor, Introduction to Biology Course Tel Aviv University 2023-2024, Instructor, “Commercializing University Research” Course
Coller School of Management, Tel Aviv University 2020, Instructor, “Graduate Record Examination Preparation Course”
Tel Aviv University 2014-2015, Teaching Assistant, “Introduction to Genetics” Course Tel Aviv University 2007-2013

Awards 🏆

The Late Breaking News Awards at the 2023 SSIEM Symposium 2023, The Ziegler Award for Research in the Field of Metabolic Disorders
2020, The Herbert and Sharon Glazer Fund Excellence Award 2017 And more…

Funding Acquired💰

The John Templeton Foundation Research Grant 2021-2024, Israel Science Foundation Research Grant 2019-2023, Momentum Fund Investment in Promising Breakthrough Technologies 2021-2023 And more…

Patents🛠️

Laor, D., & Gazit, E (2018). Integrated drug discovery platform for inborn error of metabolism disorders.
US Provisional Patent Application No. 62/779,054. Pending. Laor, D., Sade, D., and Gazit, E (2021). Integrated drug discovery platform for protein misfolding disorders associated with metabolite accumulation.
Provisional.

Conference and Scientific Meetings🌐

The first Metabolostasis conference, Israel (2023) Organizing Committee, ILASOL 36th Annual Meeting, Israel (2023)
Organizing Committee and Chair, Rare Connections 2022, Israel A conference dedicated for potential collaborations in the field of rare diseases. ISM 2022 Annual Meeting, Israel The first Israel Metabolomics Meeting, Israel (2022) And more…

Community Involvement👥

Instructor, Jewish Community Center (JCC), Ohio, USA (2002, 2003) Guided Jewish-American youth about the Israeli Culture in a youth summer camp. Armor Instructor, Israel Defense Forces (2000-2002) Served as an armor guide for regular service and reserve duty soldiers at the Armored Corps School. Counselor, “Maccabi Tzair” Youth Movement, Israel (1996-2000) Served as a counselor and teaching coordinator, mentoring and advocating Israeli youth.

📚Top Noted Publication

TOR complex 2 controls gene silencing, telomere length maintenance, and survival under DNA-damaging conditions
- Authors: M Schonbrun, D Laor, L López-Maury, J Bähler, M Kupiec, R Weisman
- Journal: Molecular and cellular biology
- Volume: 29
- Issue: 16
- Pages: 4584-4594
- Citations: 72
- Year: 2009

Two Decades of Studying Functional Amyloids in Microorganisms
- Authors: SA Levkovich, E Gazit, D Laor Bar-Yosef
- Journal: Trends in Microbiology
- Citations: 68
- Year: 2021

Fibril formation and therapeutic targeting of amyloid-like structures in a yeast model of adenine accumulation
- Authors: D Laor, D Sade, S Shaham-Niv, D Zaguri, M Gartner, V Basavalingappa, …
- Journal: Nature communications
- Volume: 10
- Issue: 1
- Pages: 62
- Citations: 54
- Year: 2019

Yeast models for the study of amyloid-associated disorders and development of future therapy
- Authors: S Rencus-Lazar, Y DeRowe, H Adsi, E Gazit, D Laor
- Journal: Frontiers in Molecular Biosciences
- Volume: 6
- Pages: 15
- Citations: 45
- Year: 2019

TORC1 regulates developmental responses to nitrogen stress via regulation of the GATA transcription factor Gaf1
- Authors: D Laor, A Cohen, M Kupiec, R Weisman
- Journal: MBio
- Volume: 6
- Issue: 4
- Citations: 33
- Year: 2015

Engineered riboswitch nanocarriers as a possible disease-modifying treatment for metabolic disorders
- Authors: S Zilberzwige-Tal, D Gazit, H Adsi, M Gartner, R Behl, D Bar-Yosef Laor, …
- Journal: ACS nano
- Volume: 16
- Issue: 8
- Pages: 11733-11741
- Citations: 3
- Year: 2022

Integrated drug discovery platform for inborn error of metabolism disorders
- Authors: E Gazit, L Dana
- Patent: US Patent App. 17/345,248
- Citations: 1
- Year: 2021

Mind your marker: the effect of common auxotrophic markers on complex traits in yeast
- Authors: K Kaplan, SA Levkovich, Y DeRowe, E Gazit, D Laor Bar‐Yosef
- Journal: The FEBS Journal
- Year: 2024

The von Hippel-Lindau protein forms fibrillar amyloid assemblies that are mitigated by the anti-amyloid molecule Purpurin
- Authors: V Kumar, V Kaushik, S Kumar, SA Levkovich, P Gupta, DL Bar-Yosef, …
- Journal: Biochemical and Biophysical Research Communications
- Volume: 690
- Pages: 149250
- Year: 2024

Branched-Chain Amino Acid Assembly into Amyloid-like Fibrils Provides a New Paradigm for Maple Syrup Urine Disease Pathology
- Authors: T Kreiser, I Sogolovsky-Bard, D Zaguri, S Shaham-Niv, D Laor Bar-Yosef, …
- Journal: International Journal of Molecular Sciences
- Volume: 24
- Issue: 21
- Pages: 15999
- Year: 2023

Srijan Acharya | Molecular Pharmacology | Excellence in Research

Dr. Srijan Acharya | Molecular Pharmacology | Excellence in Research

Dr at St. Jude Children’s Research Hospital, United States

Profile